Items where authors include "Coope, H."

Article

Arlt, W. orcid.org/0000-0001-5106-9719, Brac de la Perrière, A. orcid.org/0000-0001-6453-8326, Hirschberg, A.L. orcid.org/0000-0001-6481-6277 et al. (10 more authors) (2025) Long-term outcomes in patients with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules. European Journal of Endocrinology, 193 (1). pp. 76-84. ISSN 0804-4643

Ross, R.J.M. orcid.org/0000-0001-9222-9678, Arlt, W. orcid.org/0000-0001-5106-9719, de la Perriere, A.B. et al. (13 more authors) (2025) Switching patients with congenital adrenal hyperplasia to modified‐release hydrocortisone capsules: relative bioavailability and disease control. Clinical Endocrinology. ISSN 0300-0664

Rees, A.D., Merke, D.P., Arlt, W. et al. (12 more authors) (2024) Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia. Endocrine Connections, 13 (8). e240150. ISSN 2049-3614

Tschaidse, L., Reisch, N. orcid.org/0000-0002-7469-6069, Arlt, W. orcid.org/0000-0001-5106-9719 et al. (15 more authors) (2023) Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. European Journal of Endocrinology, 188 (1). lvac006. pp. 109-117. ISSN 0804-4643

Proceedings Paper

Prete, A., Theiler-Schwetz, V., Arlt, W. et al. (13 more authors) (2024) 12670 CHAMPAIN study: initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Ross, R.J.M., Merke, D.P., Mallappa, A. et al. (14 more authors) (2024) 7061 Incidence of adrenal crisis in Congenital Adrenal Hyperplasia (CAH) patients during a prospective monitored long-term study of modified-release hydrocortisone (MRHC) capsules, (Efmody). In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Prete, A., Theiler-Schwetz, V., Arlt, W. et al. (13 more authors) (2024) 7692 Morning cortisol levels in patients with established primary adrenal insufficiency. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Prete, A., Theiler-Schwetz, V., Arlt, W. et al. (13 more authors) (2024) 9341 CHAMPAIN Study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .